• Aneel Kapoor, Seema Shah Murad, Saima Masood, Shah Murad, Humaira Mahmood, Asia Firdous HOD Pharmacology at Akbar Niazi Teaching Hospital and Islamabad Medical & Dental College, Islamabad, Pakistan


community Health, atherogenic, dyslipidemia


The most widely recognized of the metabolic risk factors are atherogenic dyslipidemia, elevated blood pressure, and elevated
plasma glucose. Individuals with these characteristics commonly manifest a prothrombotic state and a pro -inflammatory state
as well. Atherogenic dyslipidemia consists of an aggregation of lipoprotein abnormalities including elev ated serum trigl yceri de
and apolipoprotein B (apoB), increased small LDL particles, and a reduced level of HDL cholesterol (HDL-C). The metabolic
syndrome is often referred to as if it were a discrete entity with a single cause. Available data suggest that it truly is a
syndrome, ie, a grouping of ASCVD risk factors, but one that probably has more than one cause. Regardless of cause, the
syndrome identifies individuals at an elevated risk for ASCVD. The magnitude of the increased risk can v ary according to
which components of the syndrome are present plus the other, non-metabolic syndrome risk factors in a particular person.
Design and Place of conduction: The research work was single blind placebo-controlled, conducted at Jinnah Hospital, Lahore
Research time: It was conducted from April 2021 to October 2021. Number of patients and their Age: Seventy five already
diagnosed primary and secondary hyperlipidemic patients were selected with age range from 17 to 65 years. Exclusion
criteria: Diabetes mellitus, cigarette smoking/alcohol addictive patients, peptic ulcer disease, hypothyroidism, kidney
dysfunction, any heart disease and liver disease. All patients were divided in three groups (group-I, group-II, group-III), 25 in
each group. Proforma for patients: Their baseline lipid profile data were taken and filed in specifically designed Performa, at
start of taking medicine. Patients group division: Twenty five patients of group-I were advised to take 10 grams of Flaxseeds in
three divided doses after meal. Twenty five patients of group-II were advised to take Ajwain seeds 10 grams in three divided
doses after each meal for two months. Twenty five patients of group-III were provided placebo capsul es, (containing grinded
rice), taking one capsule after each meal. All participants were advised to take these medicines for eight weeks. Follow-up
period: All participants were called fortnightly for their query and follow up. Their LDL-cholesterol and HDL-cholesterol was
determined at the hospital laboratory. Resul ts: In two months therapy by Flaxseeds decreased LDL-cholesterol from
195.11±2.11 mg/dl to 190.22±3.11 mg/dl, which is significant statistically. HDL was increased from 34.53±1.65 mg/dl to
38.97±2.29 mg/d, which is also significant change. In two months therapy by AJWAIN, LDL-c reduced from 201.51±2.62 mg/dl
to 197.11±2.66 mg/dl, which is significant statistically. HDL-cholesterol increased by Ajwain from 36.97±3.32 mg/dl to
37.45±1.87 mg/dl, which is insignificant statistically